gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Article

Send article

AKAP12 / Gravin – a candidate tumor suppressor gene is down regulated in breast cancer

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Michaela Blankenburg - Max Delbrück Center for Molecular Medicine, Department of Tumor Genetics, Berlin, Deutschland
  • Wera Hofmann - Max Delbrück Center for Molecular Medicine, Department of Tumor Genetics, Berlin
  • Susanne Seitz - Max Delbrück Center for Molecular Medicine, Department of Tumor Genetics, Berlin
  • Jana Strissel - Max Delbrück Center for Molecular Medicine, Department of Tumor Genetics, Berlin
  • Bernd Hinzmann - Signature Diagnostics AG, Potsdam
  • Siegfried Scherneck - Max Delbrück Center for Molecular Medicine, Department of Tumor Genetics, Berlin

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO068

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk178.shtml

Published: March 20, 2006

© 2006 Blankenburg et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

We identified AKAP12 (A-kinase anchoring protein) as a candidate tumor suppressor gene in breast cancer. AKAP12, also known as gravin, has been mapped on chromosome 6q24-25.2, a hot spot region of loss of heterozygosity (LOH) in breast cancer. AKAP12 is a scaffold protein involved in signalling pathways. Significant down regulation of AKAP12 expression in breast tumors was shown by cancer profiling and chip array experiments, northern blot analysis and semiquantitative RT-PCR. To correlate expression of AKAP12 mRNA and LOH at the AKAP12 locus in primary breast tumors we analysed tumor probes in comparison to matched normal genomic DNA by sequencing of different SNPs and by amplification of the gene internal marker D6S476. To evaluate whether down regulation of AKAP12 expression is due to aberrant methylation we performed methylation-specific PCR and 5’-Aza-dC treatment. Based on the expression data we investigated the effect of AKAP12 on breast cancer cell growth by transient and stabile transfection into a breast cancer cell line. Data as to the gene expression and ability of the gene to retard tumor cell growth will be presented with respect to their relevance in tumorigenesis of breast cancer.